Analyst Research Report Snapshot

Title:

Alembic Pharmaceuticals | Q1FY14 Result & Concall Update

Price:

$58.00

Provider:

IndiaNivesh Securities Pvt Ltd

Date:

08 Aug 2013

Pages:

6

Type:

AcrobatPDF

Companies referenced:

ALEM.NS

Available for Immediate Download
Summary:

Alembic Pharmaceuticals Ltd.(APL) | Q1FY14 Result & Concall Update Almost in line with estimates Revenue was above estimates on account of higher sales from International generics business: APL’s Q1FY14 revenue was above estimates & grew 16.5% y-o-y (13.3% q-o-q) to Rs 4.27 billion (V/s INSPL estimates = Rs 3.96 billion) in Q1FY13 on the back of ~86% y-o-y growth from International generics business linked with Desvenlafaxine supply to US market along with its partner Ranbaxy at the end of March 2013 & commencement of new formulation facility. APL’s domestic formulation business grew 12.1% y-o-y on the back of healthy growth of 26% in specialty business partially offset by slow growth of only 3% y-o-y in acute segment. Overall growth was partially offset by ~6% y-o-y decline in API business linked with margin rationalization strategy of the company. Valuation: At CMP of Rs 156, the stock is trading at P/E multiple of 14.2x of FY14E & 11.6 x of FY15E earnings estimates. We had recommended buy on the stock at prevailing price of Rs 49 in our “initiating coverage report released on 7th June 2012” with the target price of Rs 79 & further updated to Rs 163, which has been achieved. Anticipating ramp up in new formulation facility, ~140 bps expansion in EBITDA margins by FY15E, ~30% y-o-y growth from international regulated market, ~15%CAGR in domestic formulation business, we continue to maintain positive view on the stock. Further, we believe that Desvenalafaxine ramp up would be slow and consistent. However, we believe that all positives are factored in the stock price at current level. We value company at 12x of FY15E earnings estimates & maintain target price to Rs 163. Due to limited upside potential from current level, we revise our rating from buy to HOLD.

Why buy analyst research?

  • Institutional quality research
  • Available for Immediate Download
  • Detailed company or industry insight
  • Print or save
  • 24 hour customer support
Return to previous page without adding this item to your cart.
Email Customer Support.

About Analyst Research

Analyst research reports are available for immediate download after purchase. You will have unlimited access to the report for 24 hours after purchase, to download, print or save it as many times as you wish. Analyst Research provided by Reuters does not constitute investment advice, and is not endorsed by Reuters Research. This information is protected by copyright and intellectual property laws. More information on Analyst Research.